HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 50, 47980-47990, December 13, 2002

This Article Full Text Full Text (PDF) All Versions of this Article: 277/50/47980    most recent M207857200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Özvegy, C. Articles by Sarkadi, B. Search for Related Content PubMed PubMed Citation Articles by Özvegy, C. Articles by Sarkadi, B. Social Bookmarking                      What's this?

Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter
MODULATION OF SUBSTRATE SPECIFICITY BY A POINT MUTATION^*

Csilla Özvegy^§, András Váradi, and Balázs Sarkadi^§¶

From the  Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences and ^§ National Medical Center, Institute of Haematology and Immunology, Membrane Research Group of the Hungarian Academy of Sciences, H-1113 Budapest, Hungary

The overexpression of the human ATP-binding cassette half-transporter, ABCG2 (placenta-specific ABC transporter, mitoxantrone resistance-associated protein, breast cancer resistance protein), causes multidrug resistance in tumor cells. An altered drug resistance profile and substrate recognition were suggested for wild-type ABCG2 and its mutant variants (R482G and R482T); the mutations were found in drug-selected tumor cells. In order to characterize the different human ABCG2 transporters without possible endogenous dimerization partners, we expressed these proteins and a catalytic center mutant (K86M) in Sf9 insect cells. Transport activity was followed in intact cells, whereas the ATP binding and hydrolytic properties of ABCG2 were studied in isolated cell membranes. We found that the K86M mutant had no transport or ATP hydrolytic activity, although its ATP binding was retained. The wild-type ABCG2 and its variants, R482G and R482T, showed characteristically different drug and dye transport activities; mitoxantrone and Hoechst 33342 were transported by all transporters, whereas rhodamine 123 was only pumped by the R482G and R482T mutants. In each case, ABCG2-dependent transport was blocked by the specific inhibitor, fumitremorgin C. A relatively high basal ABCG2-ATPase, inhibited by fumitremorgin C, was observed in all active proteins, but specific drug stimulation could only be observed in the case of R482G and R482T mutants. We found that ABCG2 is capable of a vanadate-dependent adenine nucleotide trapping. Nucleotide trapping was stimulated by the transported compounds in the R482G and R482T variants but not in the wild-type ABCG2. These experiments document the applicability of the Sf9 expression system for parallel, quantitative examination of the specific transport and ATP hydrolytic properties of different ABCG2 proteins and demonstrate significant differences in their substrate interactions.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				E Kis, T Nagy, M Jani, E Molnar, J Janossy, O Ujhellyi, K Nemet, K Heredi-Szabo, and P Krajcsi Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance Ann Rheum Dis, July 1, 2009; 68(7): 1201 - 1207. [Abstract] [Full Text] [PDF]

				J. Mishra, Q. Zhang, J. L. Rosson, J. Moran, J. M. Dopp, and B. L. Neudeck Lipopolysaccharide Increases Cell Surface P-glycoprotein That Exhibits Diminished Activity in Intestinal Epithelial Cells Drug Metab. Dispos., October 1, 2008; 36(10): 2145 - 2149. [Abstract] [Full Text] [PDF]

				C. Ozvegy-Laczka, R. Laczko, C. Hegedus, T. Litman, G. Varady, K. Goda, T. Hegedus, N. V. Dokholyan, B. P. Sorrentino, A. Varadi, et al. Interaction with the 5D3 Monoclonal Antibody Is Regulated by Intramolecular Rearrangements but Not by Covalent Dimer Formation of the Human ABCG2 Multidrug Transporter J. Biol. Chem., September 19, 2008; 283(38): 26059 - 26070. [Abstract] [Full Text] [PDF]

				Y. Liu, Y. Yang, J. Qi, H. Peng, and J.-T. Zhang Effect of Cysteine Mutagenesis on the Function and Disulfide Bond Formation of Human ABCG2 J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 33 - 40. [Abstract] [Full Text] [PDF]

				H. Glavinas, E. Kis, A. Pal, R. Kovacs, M. Jani, E. Vagi, E. Molnar, S. Bansaghi, Z. Kele, T. Janaky, et al. ABCG2 (Breast Cancer Resistance Protein/Mitoxantrone Resistance-Associated Protein) ATPase Assay: A Useful Tool to Detect Drug-Transporter Interactions Drug Metab. Dispos., September 1, 2007; 35(9): 1533 - 1542. [Abstract] [Full Text] [PDF]

				I. J. Letourneau, A. J. Slot, R. G. Deeley, and S. P. C. Cole Mutational Analysis of a Highly Conserved Proline Residue in MRP1, MRP2, and MRP3 Reveals a Partially Conserved Function Drug Metab. Dispos., August 1, 2007; 35(8): 1372 - 1379. [Abstract] [Full Text] [PDF]

				A. Pal, D. Mehn, E. Molnar, S. Gedey, P. Meszaros, T. Nagy, H. Glavinas, T. Janaky, O. von Richter, G. Bathori, et al. Cholesterol Potentiates ABCG2 Activity in a Heterologous Expression System: Improved in Vitro Model to Study Function of Human ABCG2 J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1085 - 1094. [Abstract] [Full Text] [PDF]

				J. Xu, H. Peng, Q. Chen, Y. Liu, Z. Dong, and J.-T. Zhang Oligomerization Domain of the Multidrug Resistance-Associated Transporter ABCG2 and Its Dominant Inhibitory Activity Cancer Res., May 1, 2007; 67(9): 4373 - 4381. [Abstract] [Full Text] [PDF]

				C. Q. Xia, N. Liu, G. T. Miwa, and L.-S. Gan Interactions of Cyclosporin A with Breast Cancer Resistance Protein Drug Metab. Dispos., April 1, 2007; 35(4): 576 - 582. [Abstract] [Full Text] [PDF]

				P. Breedveld, D. Pluim, G. Cipriani, F. Dahlhaus, M. A. J. van Eijndhoven, C. J. F. de Wolf, A. Kuil, J. H. Beijnen, G. L. Scheffer, G. Jansen, et al. The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models Mol. Pharmacol., January 1, 2007; 71(1): 240 - 249. [Abstract] [Full Text] [PDF]

				B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol Rev, October 1, 2006; 86(4): 1179 - 1236. [Abstract] [Full Text] [PDF]

				J. Wang, F. Sun, D.-w. Zhang, Y. Ma, F. Xu, J. D. Belani, J. C. Cohen, H. H. Hobbs, and X.-S. Xie Sterol Transfer by ABCG5 and ABCG8: IN VITRO ASSAY AND RECONSTITUTION J. Biol. Chem., September 22, 2006; 281(38): 27894 - 27904. [Abstract] [Full Text] [PDF]

				C. D. Speziali, S. E. Dale, J. A. Henderson, E. D. Vines, and D. E. Heinrichs Requirement of Staphylococcus aureus ATP-Binding Cassette-ATPase FhuC for Iron-Restricted Growth and Evidence that It Functions with More than One Iron Transporter J. Bacteriol., March 15, 2006; 188(6): 2048 - 2055. [Abstract] [Full Text] [PDF]

				C. J. Henrich, H. R. Bokesch, M. Dean, S. E. Bates, R. W. Robey, E. I. Goncharova, J. A. Wilson, and J. B. McMahon A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity J Biomol Screen, March 1, 2006; 11(2): 176 - 183. [Abstract] [PDF]

				U. Henriksen, J. U. Fog, T. Litman, and U. Gether Identification of Intra- and Intermolecular Disulfide Bridges in the Multidrug Resistance Transporter ABCG2 J. Biol. Chem., November 4, 2005; 280(44): 36926 - 36934. [Abstract] [Full Text] [PDF]

				C. Albrecht, J. H. McVey, J. I. Elliott, A. Sardini, I. Kasza, A. D. Mumford, R. P. Naoumova, E. G. D. Tuddenham, K. Szabo, and C. F. Higgins A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome Blood, July 15, 2005; 106(2): 542 - 549. [Abstract] [Full Text] [PDF]

				U. Henriksen, U. Gether, and T. Litman Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2 J. Cell Sci., April 1, 2005; 118(7): 1417 - 1426. [Abstract] [Full Text] [PDF]

				N. B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Varady, O. Ujhelly, K. Szabo, L. Homolya, A. Varadi, L. Buday, et al. Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib) Cancer Res., March 1, 2005; 65(5): 1770 - 1777. [Abstract] [Full Text] [PDF]

				K. F. K. Ejendal and C. A. Hrycyna Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A Mol. Pharmacol., March 1, 2005; 67(3): 902 - 911. [Abstract] [Full Text] [PDF]

				C. Ozvegy-Laczka, G. Varady, G. Koblos, O. Ujhelly, J. Cervenak, J. D. Schuetz, B. P. Sorrentino, G.-J. Koomen, A. Varadi, K. Nemet, et al. Function-dependent Conformational Changes of the ABCG2 Multidrug Transporter Modify Its Interaction with a Monoclonal Antibody on the Cell Surface J. Biol. Chem., February 11, 2005; 280(6): 4219 - 4227. [Abstract] [Full Text] [PDF]

				S. E. Bates, W. Y. Medina-Perez, G. Kohlhagen, S. Antony, T. Nadjem, R. W. Robey, and Y. Pommier ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 836 - 842. [Abstract] [Full Text] [PDF]

				P. Krishnamurthy, D. D. Ross, T. Nakanishi, K. Bailey-Dell, S. Zhou, K. E. Mercer, B. Sarkadi, B. P. Sorrentino, and J. D. Schuetz The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme J. Biol. Chem., June 4, 2004; 279(23): 24218 - 24225. [Abstract] [Full Text] [PDF]

				C. Ozvegy-Laczka, T. Heged""s, G. Varady, O. Ujhelly, J. D. Schuetz, A. Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter Mol. Pharmacol., June 1, 2004; 65(6): 1485 - 1495. [Abstract] [Full Text] [PDF]

				J. Xu, Y. Liu, Y. Yang, S. Bates, and J.-T. Zhang Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2 J. Biol. Chem., May 7, 2004; 279(19): 19781 - 19789. [Abstract] [Full Text] [PDF]

				S. Cisternino, C. Mercier, F. Bourasset, F. Roux, and J.-M. Scherrmann Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain Barrier Cancer Res., May 1, 2004; 64(9): 3296 - 3301. [Abstract] [Full Text] [PDF]

				R. W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, P. Mistry, and S. E. Bates Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition Cancer Res., February 15, 2004; 64(4): 1242 - 1246. [Abstract] [Full Text] [PDF]

				T. Nakanishi, L. A. Doyle, B. Hassel, Y. Wei, K. S. Bauer, S. Wu, D. W. Pumplin, H.-B. Fang, and D. D. Ross Functional Characterization of Human Breast Cancer Resistance Protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus laevis Mol. Pharmacol., December 1, 2003; 64(6): 1452 - 1462. [Abstract] [Full Text] [PDF]

				G. A. Graf, L. Yu, W.-P. Li, R. Gerard, P. L. Tuma, J. C. Cohen, and H. H. Hobbs ABCG5 and ABCG8 Are Obligate Heterodimers for Protein Trafficking and Biliary Cholesterol Excretion J. Biol. Chem., November 28, 2003; 278(48): 48275 - 48282. [Abstract] [Full Text] [PDF]

				Y. Imai, S. Asada, S. Tsukahara, E. Ishikawa, T. Tsuruo, and Y. Sugimoto Breast Cancer Resistance Protein Exports Sulfated Estrogens but Not Free Estrogens Mol. Pharmacol., September 1, 2003; 64(3): 610 - 618. [Abstract] [Full Text] [PDF]

				S. Kawabata, M. Oka, H. Soda, K. Shiozawa, K. Nakatomi, J. Tsurutani, Y. Nakamura, S. Doi, T. Kitazaki, K. Sugahara, et al. Expression and Functional Analyses of Breast Cancer Resistance Protein in Lung Cancer Clin. Cancer Res., August 1, 2003; 9(8): 3052 - 3057. [Abstract] [Full Text] [PDF]

				M. Suzuki, H. Suzuki, Y. Sugimoto, and Y. Sugiyama ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics J. Biol. Chem., June 13, 2003; 278(25): 22644 - 22649. [Abstract] [Full Text] [PDF]

				T. Janvilisri, H. Venter, S. Shahi, G. Reuter, L. Balakrishnan, and H. W. van Veen Sterol Transport by the Human Breast Cancer Resistance Protein (ABCG2) Expressed in Lactococcus lactis J. Biol. Chem., May 30, 2003; 278(23): 20645 - 20651. [Abstract] [Full Text] [PDF]